CLINICAL TRIALS PROFILE FOR INLYTA
✉ Email this page to a colleague
All Clinical Trials for inlyta
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00700258 ↗ | Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] | Recruiting | Pfizer | 2008-01-04 | The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use | |
NCT01321437 ↗ | Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | Completed | Pfizer | Phase 2 | 2011-12-01 | The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma. |
NCT01321437 ↗ | Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma | Completed | University of California, Irvine | Phase 2 | 2011-12-01 | The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for inlyta
Condition Name
Clinical Trial Locations for inlyta
Trials by Country
Clinical Trial Progress for inlyta
Clinical Trial Phase
Clinical Trial Sponsors for inlyta
Sponsor Name